Braftovi

Express Scripts
Prior Authorization
Phone 1-844-424-8886
Fax 1-877-251-5896

To start your Part D Coverage Determination request, you (or your representative or your doctor or other prescriber) should contact Express Scripts, Inc (ESI):

- You may Call ESI at 1-844-424-8886, 24 hours a day, 7 days a week,
  TTY users: 1-800-716-3231
- You may Fax your request to: 1-877-251-5896 (Attention: Medicare Reviews)
- You may also send your request via email to: medicarepartdparequests@express-scripts.com

Member's Last Name:	Member's First Name:
SCAN ID number:	Date of Birth:
Prescriber's Name:	Contact Person:
Office phone:	Office Fax:
Medication:	Diagnosis:

SECTION A Please answer the following questions

1. θ Yes θ No Is the member currently taking the requested medication?

2. θ Yes θ No Is Braftovi being used in combination with cetuximab for the treatment of metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test (e.g., Qiagen therascreen BRAF V600E RGQ PCR Kit, etc.) after prior therapy (e.g., irinotecan, etc.)? ***(If Yes, skip to question 9)***

3. θ Yes θ No Is Braftovi being used in combination with cetuximab and mFOLFOX for the treatment of metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test (e.g., Qiagen therascreen BRAF V600E RGQ PCR Kit, etc.)? ***(If Yes, skip to question 9)***

4. θ Yes θ No Is Braftovi being used in combination with binimetinib (Mektovi) for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation, as detected by an FDA-approved test (e.g., Oncomine Dx Target Test, etc.)? ***(If No, skip to 6)***

5. θ Yes θ No Has the member used Zelboraf or Tafinlar prior to the initiation of Braftovi? ***(If Yes, skip to 10)***

6. θ Yes θ No Is Braftovi being used in combination with binimetinib (Mektovi) for the treatment of unresectable or metastatic melanoma with a BRAF V600K mutations as detected by an FDA-approved test (e.g., Oncomine Dx Target Test, etc.)? ***(If Yes, skip to 8)***

7. θ Yes θ No Is Braftovi being used in combination with binimetinib (Mektovi) for the treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test?

8. θ Yes θ Yes Has the member used Tafinlar prior to the initiation of Braftovi?

9. θ Yes θ No Will encorafenib (Braftovi) be used concomitantly with strong or moderate CYP3A inducers (for example, rifampin, carbamazepine, phenytoin, etc.)?

10. θ Yes θ No Will baseline serum electrolytes (for example, potassium, magnesium, etc.) be performed prior to initiation of encorafenib (Braftovi)?

11. θ Yes θ No Is the prescription written or recommended by an Oncologist, Hematologist, Gastroenterologist, or Pulmonologist?

Please document the symptoms and/or any other information important to this review:

SECTION B Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-877-251-5896

Our response time for prescription drug coverage standard requests is 72 hours. If you or your prescriber believe that waiting 72 hours for a standard decision could seriously harm your life, health, or ability to regain maximum function, you can ask for an expedited (fast) decision. If your prescriber indicates that waiting 72 hours could seriously harm your health, we will automatically give you a decision within 24 hours. If you do not obtain your prescriber's support for an expedited request, we will decide if your case requires a fast decision. You cannot request an expedited coverage determination if you are asking us to pay you back for a drug you already received. View our formulary and Prior Authorization criteria online at http://www.scanhealthplan.com